<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01878201</url>
  </required_header>
  <id_info>
    <org_study_id>A657-BR-CT-L201</org_study_id>
    <nct_id>NCT01878201</nct_id>
  </id_info>
  <brief_title>A Valsartan 80 Mg-Referenced, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension</brief_title>
  <official_title>A Randomized, Double-blind, Valsartan 80 Mg-Referenced, Parallel Grouped, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyungpook National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to Evaluate the Antihypertensive efficacy of Fimasartan 30 mg
      during 24 hours in Patients with Mild to Moderate Essential Hypertension
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Systolic Blood Pressure during 24 hours</measure>
    <time_frame>8 weeks from baseline visit</time_frame>
    <description>To compare the difference of Mean Systolic Blood Pressure during 24 hours at 8 weeks from baseline visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Diastolic Blood Pressure during 24 hours</measure>
    <time_frame>8 weeks from baseline visit</time_frame>
    <description>To compare the difference of Mean Diastolic Blood Pressure during 24 hours at 8 weeks from baseline visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Diastolic Blood pressure and Systolic Blood pressure during daytime or nighttime</measure>
    <time_frame>8 weeks from baseline visit</time_frame>
    <description>To compare the difference of Diastolic Blood pressure and Systolic Blood pressure during daytime or nighttime at 8 weeks from baseline visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sitting Diastolic Blood pressure and Systolic Blood pressure</measure>
    <time_frame>8 weeks from baseline visit</time_frame>
    <description>To compare the difference of Sitting Diastolic Blood pressure and Systolic Blood pressure at 8 weeks from baseline visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough-to-peak ratio</measure>
    <time_frame>8 weeks from baseline visit</time_frame>
    <description>Trough-to-peak ratio of systolic blood pressure and diastolic blood pressure measured by ABP(Ambulatory Blood Pressure) monitor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Smoothness index</measure>
    <time_frame>8 weeks from baseline visit</time_frame>
    <description>Smoothness index of systolic blood pressure and diastolic blood pressure measured by ABP monitor</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>about 10~11weeks from placebo run-in visit</time_frame>
    <description>Adverse evnt(AE)s are collected as a safety measure. All AEs are arranged based on severity, relevance to the investigational drug and serious adverse event each.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse changes in laboratory test results</measure>
    <time_frame>about 10~11weeks from screening visit</time_frame>
    <description>Adverse changes in laboratory test results are collected as a safety measure. As a continuous data group for each test visit, adverse changes in laboratory test results present descriptive statistics (mean, standard deviation, minimum, maximum, etc.)</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse changes in electrocardiography(ECG)</measure>
    <time_frame>about 10~11weeks from screening visit</time_frame>
    <description>Adverse changes in ECG are collected as a safety measure. As a categorical data, adverse changes in ECG present frequency and percentage for each category.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>Fimasartan 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Take one capsule filled with a Fimasartan 30 mg in the every morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan 80 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Take one capsule filled with a Valsartan 80 mg in the every morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan</intervention_name>
    <description>Fimasartan 30 mg</description>
    <arm_group_label>Fimasartan 30 mg</arm_group_label>
    <other_name>Kanarb</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>Valsartan 80 mg</description>
    <arm_group_label>Valsartan 80 mg</arm_group_label>
    <other_name>Diovan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects aged 20 to 70 years

          2. Essential hypertension subjects who are measured more 135/85 mmHg of average Diastolic
             Blood pressure (DBP) and Systolic Blood pressure (SBP) measured by ABP monitor at
             baseline visit(day 0)

          3. Subjects who agreed to participate in this study and submitted the written informed
             consent

          4. Subjects who considered to understand this study, be cooperative, and able to be
             followed-up whole of the study period

        Exclusion Criteria:

          1. Severe hypertension patients; more 180 mmHg of mean sitting SBP and/or more 110 mmHg
             of mean sitting DBP measured as an office Blood pressure (BP), before Randomization
             (Screening visit, Placebo run-in visit, Pre-Baseline visit, Baseline visit)

          2. Patients with difference of office BP at selected one arm over DBP 10 mmHg and/or SBP
             20 mmHg at screening visit

          3. Patients with secondary hypertension

          4. Patients with symptomatic orthostatic hypotension

          5. Patients with severe insulin dependent or uncontrolled diabetes mellitus (HbA1c &gt; 9%,
             increased regimen of oral hypoglycemic agent, using insulin at baseline visit)

          6. Patients with severe heart disease, ischemic heart disease within 6 months, peripheral
             vascular disease, Percutaneous Transluminal Coronary Angiography (PTCA), Coronary
             Artery Bypass Graft (CABG)

          7. Patients with significant ventricular tachycardia, atrial fibrillation, atrial flutter
             or other significant arrhythmia

          8. Patients with hypertrophic obstructive cardiomyopathy, severe obstructive coronary
             artery disease, aortic stenosis, hemodynamically significant aortic valve or mitral
             valve disease

          9. Patients with severe cerebrovascular disease within 6 months

         10. Patients with known severe or malignancy retinopathy within 6 months

         11. Patients with wasting disease, autoimmune disease, connective tissue disease

         12. Patients with significant investigations - abnormal renal function (Creatinine more
             1.5 times than upper limit of normal), abnormal liver function (Aspartate
             Transaminase(AST), Alanine Transaminase(ALT) more 2 times than upper normal)

         13. Patients with surgical or medical disease which is able to be affect to absorption,
             distribution, metabolism, excretion

         14. Patients with hereditary disorders of galactose intolerance, Lapp lactase deficiency
             or glucose-galactose malabsorption

         15. Patients with significant investigations - Hypokalemia(Less than 3.5mmol/L),
             Hyperkalemia(exceeded 5.5mmol/L)

         16. Patients with depletion of body fluid or sodium ion not able to correct

         17. Patients with suspected or history of drug or alcohol abuse within the past two years

         18. Childbearing, breast-feeding women and female who plan to become pregnancy or have a
             possibility of pregnancy but don't prevent conception with acknowledged methods

         19. Patients with any chronic inflammation disease needed to chronic inflammation therapy

         20. Patients with hepatitis type B or type C and carriers

         21. Patients with laboratory test results indicating clinically significant abnormal
             results

         22. Patients receiving medication that can affect blood pressure

         23. Patients with history of allergic reaction to any angiotensin II antagonist

         24. Patients with the medical histories of malignant tumor within 5years, except local
             basal cell carcinoma of the skin

         25. Patients who took investigational drug within 12 weeks from screening visit or is
             going on the progress of other clinical trial

         26. Subject who are judged unsuitable to participate in this study by investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Byung-He Oh, professor</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2013</study_first_submitted>
  <study_first_submitted_qc>June 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2013</study_first_posted>
  <last_update_submitted>September 5, 2014</last_update_submitted>
  <last_update_submitted_qc>September 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fimasartan</keyword>
  <keyword>24 hours ABP monitoring(ABPM)</keyword>
  <keyword>antihypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

